Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma: Its association with tumor progression and its significant decrease after curative surgical resection

Cancer

Volumn 85, Issue 3, 1999, Pages 554-561

  Shim, Kang Sup ^a,b   Kim, Kwang Ho ^a   Han, Woon Sup ^a   Park, Eung Bum ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Mokdong Hospital   (South Korea)

Author keywords

Biomarker; Colorectal carcinoma; Enzyme linked immunoadsorbent assay (ELISA); Serum; Transforming growth factor (TGF) 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANALYSIS OF VARIANCE; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0006335227     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X     Document Type: Article

References (45)

1. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-82.
2. Huang F, Newman E, Theodorescu D, Kerbel RS, Friedamn E. Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. Cell Growth Differ 1995;6:1635-42.
3. MacKay SL, Yaswen LR, Tarnuzzer RW, Moldawer LL, Bland KI, Copeland EM, et al. Colon cancer cells that are not growth inhibited by TGF-beta lack functional type I and type II TGF-beta receptors. Ann Surg 1995;221:767-76.
4. Markowitz S, Wang J, Myenoff L, Parsons R, Sun LZ, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-38.
5. Brattain MG, Markowitz SD, Willson JKV. The type II transforming growth factor-beta receptor as a tumor-suppressor gene. Curr Opin Oncol 1996;8:49-53.
6. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
7. Gryfe R, Bapat B, Gallinger S, Swallow C, Redston M, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer 1997;21:233-300.
8. Jiang W, Tillekeratne MPM, Brattain MG, Banerji SS. Decreased stability of transforming growth factor beta type II receptor mRNA in RER+ human colon carcinoma cells. Biochemistry 1997;36:14786-93.
9. Wu S, Theodorescu D, Kerbel RS, Willson JKV, Mulder KM, Humphrey LE, et al. TGF-β1 is an autocrine negative regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 1992;116:187-96.
10. Shimizu S, Nishikawa Y, Kuroda K, Tagaki S, Kozaki K, Hyuga S, et al. Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996; 56:3366-70.
11. Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression. Cell Growth Differ 1994;5:267-75.
12. Hafez MM, Infante D, Winawer S, Friedman E. TGF-β1 acts as an autocrine-negative growth regulator in colon enterocyteic differentiation but no in goblet cell maturation. Cell Growth Differ 1990;1:617-26.
13. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H. Serum markers for fibrosis and plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis. J Gastroenterol Hepatol 1996;11:443-50.
14. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996;16:47-59.
15. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H. Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol 1996;156:953-7.
16. Comerci JT Jr, Runowicz CD, Flanders KC, De Victoria C, Fiels AL, Kadish AS, et al. Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer 1996;77:1107-14.
17. Migdalska A, Molineux G, Demuynck H, Evans GS, Ruscetti F, Dexter TM. Growth inhibitory effects of TGF-β1 in vivo. Growth Factors 1991;4:239-45.
18. Schroy P, Rikfin J, Coffey RJ, Winawer S, Friedman E. Role of TGF-β1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. Cancer Res 1990;50:261-5.
19. Manning AM, Williams AC, Game SM, Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to TGF-β: conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β. Oncogene 1991;6: 1471-6.
20. Hague A, Manning AM, van der Stappen JWJ, Paraskeva C. Escape from negative regulation of growth by transforming growth factor beta and from the induction of apoptosis by the dietary agent sodium bytyrate may be important in colorectal carcinogenesis. Cancer Metastasis Rev 1993;12: 227-37.
21. de Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M. Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol Res 1997;9:89-98.
22. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H. Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas. Br J Cancer 1997;75:1753-60.
23. Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 1997;123:167-72.
24. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes RC. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 1993;67: 1408-12.
25. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995;4:549-54.
26. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for TGF-β1 associates with disease progression in human breast cancer. Cancer Res 1992; 52:6949-52.
27. Chakrabarty S, Tobon A, Varani J, Brattain MG. Induction of carcinoembryonic antigen secretion and modulation of protein secretion/expression and fibronectin/laminin expression in human colon carcinoma cells by transforming growth factor-B. Cancer Res 1988;48:4059-64.
28. Chakrabarty S, Huang S. Role of protein kinase Cα in the induction of carcinoembryonic antigen by transforming growth factor β1. J Cell Physiol 1995;164:148-53.
29. Huang S, Chakrabarty S. Expression of antisense fibronectin RNA in human colon carcinoma cells disrupts the regulation of carcinoembryonic antigen by transforming growth factor beta 1. J Biol Chem 1994;269:28764-8.
30. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marogi OL, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997;74:492-501.
31. Inoue T, Ishida T, Takenoyama M, Sugio K, Sugimachi K. The relationship between the immunodetection of transforming growth factor-beta in lung adenocarcinoma and longer survival rates. Surg Oncol 1995;4:51-7.
32. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
33. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996;74:753-8.
34. Takanami I, Tanaka F, Hashizume T, Kodaira S. Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol 1997;64:262-7.
35. Takanami I, Tanaka F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, et al. Transforming growth factor-beta isoforms expressions in pulmonary adenocarcinomas as prognostic markers: an immunohistological study of one hundred and twenty patients. Oncology 1997;54:122-8.
36. Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Kodaira S. Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol 1994;47:1098-100.
37. Steiner MS, Barrack ER. Transforming growth factor beta1 oberproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
38. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997;76:244-50.
39. Auvinen P, Lipponen P, Johansson R, Syrjanen K. Prognostic significance of TGF-beta 1 and TGF-beta 2 expressions in female breast cancer. Anticancer Res 1995;15:2627-31.
40. Earth RJ Jr. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer 1996;78:1168-78.
41. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994;73:2275-9.
42. Hirakata Y, Katamura S. Elevated serum transforming growth factor beta 1 level in primary lung cancer patients with finger clubbing. Eur J Clin Invest 1996;26:820-3.
43. Junker U, Knoefel B, Nuske K, Rebstock K, Steiner T, Wunderlich H, et al. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 1996;8:794-8.
44. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, et al. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl 1992; 16H:54-61.
45. Perry KT, Anthony CT, Case T, Steiner MS. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 1997;49:151-5.